Literature DB >> 11920743

Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions.

Lieve Brochez1, Evelien Verhaeghe, Edouard Grosshans, Eckhart Haneke, Gérald Piérard, Dirk Ruiter, Jean-Marie Naeyaert.   

Abstract

When a biopsy is taken of a suspicious pigmented skin lesion, histological examination is expected to establish the definitive diagnosis. This study evaluated the inter-observer variation of 20 pathologists in the histological diagnosis of a randomly selected set of suspicious pigmented skin lesions (PSLs), by comparing their diagnoses to a reference diagnosis. Overall sensitivity for melanoma was 87%, ranging from 55% to 100% between the observers. Sensitivity was significantly lower for thin (Breslow thickness <1 mm) than for thick melanomas (83% versus 97%, p=0.005). Overall melanoma specificity was 94%, ranging from 83% to 100% between observers. Dysplastic naevus was the most important source of false-positive diagnoses, mainly in situ melanomas. Positive and negative predictive values in the given test set were 75% and 97%, respectively. In the case of melanoma, there was quite some variation in measured Breslow thickness. This would have led to a different therapeutic approach in 12% of the readings. Some of the variation seemed to be due to a different interpretation of the presence of a co-existent naevus. In 9% (3/35) of the readings, participants did not agree on the presence of ulceration. These results reflect a tendency to overdiagnose mainly thin melanomas in general histopathological practice. They also demonstrate variation in the assessment of major prognostic factors of melanoma. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 11920743     DOI: 10.1002/path.1061

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  27 in total

1.  MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations.

Authors:  Grant E Nybakken; Michael Sargen; Ronnie Abraham; Paul J Zhang; Michael Ming; Xiaowei Xu
Journal:  Am J Dermatopathol       Date:  2013-02       Impact factor: 1.533

2.  The MPATH-Dx reporting schema for melanocytic proliferations and melanoma.

Authors:  Michael W Piepkorn; Raymond L Barnhill; David E Elder; Stevan R Knezevich; Patricia A Carney; Lisa M Reisch; Joann G Elmore
Journal:  J Am Acad Dermatol       Date:  2013-10-28       Impact factor: 11.527

3.  Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.

Authors:  Laura K Ferris; Burkhard Jansen; Jonhan Ho; Klaus J Busam; Kenneth Gross; Doyle D Hansen; John P Alsobrook; Zuxu Yao; Gary L Peck; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

4.  The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

5.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

6.  Histologic review of melanomas by pathologists trained in melanocytic lesions may change therapeutic approach in up to 41.9% of cases.

Authors:  Nathalie Mie Suzuki; Maria Isabel Ramos Saraiva; Gabriela Cunha Capareli; Luiz Guilherme Martins Castro
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

7.  Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Authors:  Kathleen Conway; Sharon N Edmiston; Joel S Parker; Pei Fen Kuan; Yi-Hsuan Tsai; Pamela A Groben; Daniel C Zedek; Glynis A Scott; Eloise A Parrish; Honglin Hao; Michelle V Pearlstein; Jill S Frank; Craig C Carson; Matthew D Wilkerson; Xiaobei Zhao; Nathaniel A Slater; Stergios J Moschos; David W Ollila; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2018-12-06       Impact factor: 8.551

8.  Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Kenneth M Boucher; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-12-16       Impact factor: 11.527

9.  Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Authors:  Linda Gao; Karin van den Hurk; Peter T M Moerkerk; Jelle J Goeman; Samuel Beck; Nelleke A Gruis; Joost J van den Oord; Véronique J Winnepenninckx; Manon van Engeland; Remco van Doorn
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

10.  A multi-marker assay to distinguish malignant melanomas from benign nevi.

Authors:  Mohammed Kashani-Sabet; Javier Rangel; Sima Torabian; Mehdi Nosrati; Jeff Simko; David M Jablons; Dan H Moore; Chris Haqq; James R Miller; Richard W Sagebiel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.